Combined pharmacokinetic and urodynamic study of the effects of oral administration of phenylpropanolamine in female Beagle dogs

Veterinary Journal

Volumn 184, Issue 2, 2010, Pages 201-207

  Noël, Stéphanie ^a   Cambier, Carole ^a   Baert, Kris ^b   Gustin, Pascal ^a   Denooz, Raphael ^a   Massart, Laurent ^a   Hamaide, Annick ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Agonist; Haemodynamics; Half life; Maximal plasma concentration; Urethral resistance

Indexed keywords

PHENYLPROPANOLAMINE; PROPALIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLADDER SPHINCTER; BRADYCARDIA; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HEMODYNAMICS; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; MORNING DOSAGE; NONHUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION; URETHRA PRESSURE; URINE INCONTINENCE; URODYNAMICS;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-AGONISTS; ANIMALS; AREA UNDER CURVE; BLOOD PRESSURE; CROSS-OVER STUDIES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMODYNAMICS; KINETICS; PHENYLPROPANOLAMINE; RANDOM ALLOCATION; URODYNAMICS;

CANIS FAMILIARIS;

EID: 77649089075     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tvjl.2009.01.026     Document Type: Article

References (48)

1. Andersson K.E. The pharamacology of the lower urinary tract smooth muscles and penile erectile tissues. Pharmacological Reviews 45 (1993) 253-308
2. Auguet M., Delaflotte S., and Chabrier P.-E. Different α1-adrenoreceptor subtypes mediate contraction in rabbit aorta and urethra. European Journal of Pharmacology 287 (1995) 153-161
3. Barst R., and Abenhaim L. Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure. Heart 290 (2004) e42
4. Boothe D. Principles of drug therapy. In: Boothe D. (Ed). Small Animal Clinical Pharmacology and Therapeutics (2001), W.B Saunders Company, Philadelphia, USA 3-17
5. Boron W., and Boulpaep E. Medical Physiology. second ed. (2005), Elsevier Saunders, Philadelphia, USA 1319 p
6. Brunton L., Lazo J., and Parker K. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 11th ed. (2006), McGraw-Hill Companies, USA 2021 p
7. Burgherr T., Reichler I., Hung L., Hubler M., and Arnold S. Efficacy, tolerance and acceptability of Incontex in the context of spayed bitches with urinary incontinence. Schweizer Archiv Tierheilkund 149 (2007) 307-313
8. Callahan S., and Creed K. The effects of oestrogens on spontaneous activity and responses to phenylephrine of the mammalian urethra. Journal of Physiology 358 (1985) 35-46
9. Carofiglio F., Hamaide A., Farnir F., Balligand M., and Verstegen J. Evaluation of the urodynamic and hemodynamic effects of orally administered phenylpropanolamine and ephedrine in female dogs. American Journal of Veterinary Research 67 (2006) 723-730
10. Cohn L., Dodam J., and Szladovits B. Effects of selegine, phenylpropanolamine or a combination of both on physiologic and behavioural variables in healthy dogs. American Journal of Veterinary Research 63 (2002) 827-832
11. Collins S., Caron M., and Lefkrowitz R. Regulation of adrenergic receptor responsiveness through modulation of receptor gene expression. Annual Review of Physiology 53 (1991) 497-508
12. Collste L., and Lindskog M. Phenylpropanolamine in treatment of female stress urinary incontinence. Double-blind placebo controlled study in 24 patients. Urology 30 (1987) 398-403
13. Delorio N. Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication. The Journal of Emergency Medicine 26 (2004) 305-307
14. DiBartola S., and Adams W. Urinary incontinence associated with malposition of the urinary bladder. In: Kirk R. (Ed). Current Veterinary Therapy VII. Small Animal Practice (1983), WB Saunders Co., Philadelphia, USA 1089-1092
15. Finkbeiner A., and Bissida N. Drug therapy for lower urinary tract dysfunction. The Urologic Clinics of North America 7 (1980) 3-16
16. Haller C., and Benowitz N. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. New England Journal of Medicine 343 (2000) 1833-1838
17. Hamaide A., Vestegen J., Snaps F., Onclin K., and Balligand M. Validation and comparison of the use of diuresis cystometry and retrograde filling cystometry at various infusion rate in female Beagle dogs. American Journal of Veterinary Research 64 (2003) 574-579
18. Hashimoto S., Kigoshi S., and Muramatsu I. Neurogenic responses of urethra isolated from the dog. European Journal of Pharmacology 213 (1992) 117-123
19. Hensel P., Binder H., and Arnold S. Influence of phenylpropanolamine and ephedrine on the urethral closure pressure and the arterial blood pressure of spayed bitches. Kleintierpraxis 45 (2000) 617-628
20. Holt P. Urinary incontinence in the bitch due to sphincter mechanism incompetence: prevalence in referred dogs and retrospective analysis of sixty cases. Journal of Small Animal Practice 26 (1985) 181-190
21. Holt P. Urinary incontinence in dogs and cats. Veterinary Record 127 (1990) 347-350
22. Holt P., Gibbs C., and Wathes C. Simultaneous urethral profile profilometry using a microtip transducer catheter in the bitch: effects of position and transducer orientation. Neurourology Urodynamic 9 (1990) 281-296
23. Hussain M., Aungst B., Lam G., and Shefter E. Phenylpropanolamine: pharmacokinetics in dogs after intravenous, oral, and oral controlled-release doses. Biopharmaceutics and Drug Disposition 8 (1987) 497-505
24. International Continence Society. First report on the standardisation of terminology of lower urinary tract function. British Journal of Urology 48 (1976) 39-42
25. Johnston S., Root Kustritz M., and Olson P. Vaginal cytology. In: Johnston S., Root Kustritz M., and Olson P. (Eds). Canine and Feline Theriogenology (2001), WB Saunders Co., Philadelphia, USA 32-40
26. Johnston S., Root Kustritz M., and Olson P. The canine estrous cycle. In: Johnston S., Root Kustritz M., and Olson P. (Eds). Canine and Feline Theriogenology (2001), WB Saunders Co., Philadelphia, USA 17-29
27. Kernam W., Viscoli C., Brass L., Broderick J., Brott T., Feldmann E., Morgenstem L., Wilterdink J., and Horwitz R. Phenylpropanolamine and the risk of hemorrhagic stroke. New England Journal of Medicine 343 (2000) 1826-1832
28. Kittelson M., and Kienle R. Syncope. In: Kittelson M., and Kienle R. (Eds). Small Animal Cardiovascular Medicine (1998), Mosby Inc., St Louis, MO, USA 495-501
29. Krawiec D. Urinary incontinence in dogs and cats. Modern Veterinary Practice 69 (1988) 17-24
30. Labato M. Micturition disorders. Handbook of Small Animal Practice (1988), R.V. Morgan, New York, USA 621-628
31. Lasagna L. Chemistry. Phenylpropanolamine: a review (1988), John Wiley and Sons, New York, USA 40 p
32. Lehtonen T., Rannikko S., Lindell O., Talja M., Wuokko E., and Lindskog M. The effects of phenylpropanolamine on female stress urinary incontinence. Annales Chirurgicae et Gynaecologiae 75 (1986) 236-241
33. Lentner C. Statistical methods. Introduction to Statistics (1982), Ciba-Geigy, Basle, Switzerland 182-236
34. Lohse M. Molecular mechanisms of membrane receptor desensitization. Biochimica et Biophysica Acta 1179 (1993) 171-188
35. 1-adrenergic receptors and contraction of rat vas deferens. Molecular Pharmacology 23 (1983) 359-368
36. Moreau P., and Lappin M. Pharmacologic management of micturition. In: Kirk R., and Bonagura J. (Eds). Current Veterinary Therapy X. Small Animal Practice (1989), WB Saunders Co., Philadelphia, USA 1214-1216
37. Pentel P., Asinger R., and Benowitz N. Propanolol antagonism of phenylpropanolamine-induced hypertension. Clinical Pharmacology and Therapeutics 37 (1985) 488-494
38. Per-Göran G., Fredrickson M., Ohman B., and Alberts P. The effect of phenylpropanolamine on the urethral pressure and heart rate is retained after repeated short-term administration in the unanaesthetized, conscious dog. Scandinavian Journal of Urology and Nephrology 32 (1998) 171-176
39. Persson C., Erjefalt I., and Keman M. Brompheniramine and the cardio-vascular effects of norephedrine and noradrenaline. Acta Allergologica 28 (1973) 401-415
40. Pilsczek F., Karcic A., and Freeman I. Case report: dexatrim (phenylpropanolamine) as a cause of myocardial infarction. Heart Lung 32 (2003) 100-104
41. Ritcher K., and Ling G. Clinical response and urethral pressure profile changes after phenylpropanolamine in dogs with primary sphincter incompetence. Journal of American Veterinary Medicine Association 187 (1985) 605-611
42. Scherzinger S., Dowse R., and Kanfer I. Steady state pharmacokinetics and dose-proportionality of phenylpropanolamine in healthy subjects. Journal of Clinical Pharmacology 30 (1990) 372-377
43. Scott L., Leddy M., Bernay F., and Davot J. Evaluation of phenylpropanolamine in the treatment of urethral sphincter mechanism incompetence in the bitch. Journal of Small Animal Practice 43 (2002) 493-496
44. Stevens M., and Moulds R. Heterogeneity of post-junctional α-adrenoceptors in human vascular smooth muscle. Archives Internationales de Pharmacodynamie et de Thérapie 254 (1981) 43-57
45. Stevens M., Rittinghausen R., and Moulds R. Heterogeneity of human vascular pre- and post-synaptic α-adrenoceptors. Clinical Science 61 (1981) 202-206
46. Sullivan J., and Abrams P. Pharmacological management of incontinence. European Urology 36 (1999) 89-95
47. Vick J., Weiss L., and Ellis S. Cardiovascular studies of phenylpropanolamine. Archive International de Pharmacodynamie 327 (1994) 13-24
48. White R., and Pomeroy C. Phenylpropanolamine: an alpha-adrenergic agent for management of urinary incontinence in the bitch with urethral sphincter mechanism incompetence. Veterinary Record 125 (1989) 478-480